HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals (Q38083295)

28 August 2017

title

HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals (English)

1 reference

28 August 2017

main subject

visceral leishmaniasis

1 reference

Marleen Boelaert

4

0 references

Asrat Hailu

8

object named as

Asrat Hailu

1 reference

28 August 2017

1

Johan van Griensven

1 reference

28 August 2017

Ermias Diro

2

1 reference

28 August 2017

Rogelio Lopez-Velez

3

1 reference

28 August 2017

Lutgarde Lynen

5

1 reference

28 August 2017

Ed Zijlstra

6

1 reference

28 August 2017

Jean-Claude Dujardin

7

1 reference

28 August 2017

publication date

1 March 2013

1 reference

Lancet Infectious Diseases

28 August 2017

published in

1 reference

28 August 2017

volume

13

1 reference

28 August 2017

issue

3

1 reference

28 August 2017

page(s)

251-259

1 reference

28 August 2017

cites work

Visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Combination therapy for visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Leishmaniasis worldwide and global estimates of its incidence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

The relationship between leishmaniasis and AIDS: the second 10 years

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

The impact of HIV-protease inhibitors on opportunistic parasites

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Effects of HIV aspartyl-proteinase inhibitors on Leishmania sp.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Antileishmanial activity of HIV protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Lopinavir/ritonavir: a review of its use in the management of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Nelfinavir, an HIV-1 protease inhibitor, induces oxidative stress-mediated, caspase-independent apoptosis in Leishmania amastigotes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

HIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Effect of HIV protease inhibitors on New World Leishmania

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

HIV proteinase inhibitors target the Ddi1-like protein of Leishmania parasites

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Aspartic peptidase inhibitors: implications in drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

A novel family of predicted retroviral-like aspartyl proteases with a possible key role in eukaryotic cell cycle control

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Ddi1, a eukaryotic protein with the retroviral protease fold

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Linking in vitro and in vivo survival of clinical Leishmania donovani strains

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Molecular mechanisms of drug resistance in natural Leishmania populations vary with genetic background

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

The human 26S proteasome is a target of antiretroviral agents.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

The Leishmania mexicana proteasome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Molecular characterization of a Leishmania donovanii cDNA clone with similarity to human 20S proteasome a-type subunit.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Protease inhibitors as immunomodulatory drugs for HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Flying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Differential effects of HIV-1 protease inhibitors on dendritic cell immunophenotype and function

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Effect of a human immunodeficiency virus protease inhibitor on human monocyte function

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Class-sparing regimens for initial treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CP

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Prospective Evaluation and Follow-Up of European Patients with Visceral Leishmaniasis and HIV-1 Coinfection in the Era of Highly Active Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Development of protease inhibitors for protozoan infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Effects of serine protease inhibitors on viability and morphology of Leishmania (Leishmania) amazonensis promastigotes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

Cysteine peptidases CPA and CPB are vital for autophagy and differentiation in Leishmania mexicana.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970348-1

7 January 2021

10.1016/S1473-3099(12)70348-1

Identifiers

DOI

1 reference

28 August 2017

1 reference